清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Real World Use and Effects of Calcimimetics in Treating Mineral and Bone Disorder in Hemodialysis Patients

西那卡塞特 拟钙质 医学 泌尿科 中止 内科学 甲状旁腺切除术 甲状旁腺激素 继发性甲状旁腺功能亢进 内分泌学 血液透析 甲状旁腺功能亢进
作者
Mark D. Danese,Deborah P. Lubeck,Vasily Belozeroff,Tzu‐Chieh Lin,Pooja Desai,Michelle Gleeson,Kévin Martin,Michel Chonchol
出处
期刊:American Journal of Nephrology [S. Karger AG]
卷期号:51 (10): 815-822 被引量:5
标识
DOI:10.1159/000510360
摘要

<b><i>Background:</i></b> Calcimimetics are used to treat mineral and bone disorder by reducing parathyroid hormone (PTH), calcium (Ca), and phosphorus (Phos). The study objectives were to assess the control of PTH, Ca, and Phos over time in patients receiving cinacalcet or etelcalcetide as well as dosing and time to discontinuation for etelcalcetide. <b><i>Methods:</i></b> This was a retrospective cohort study using electronic medical records from small and independent dialysis centers. Adults ≥18 years of age were identified as cinacalcet or etelcalcetide users based on the first calcimimetic received in 2018 (index date). Patients were followed from the index date until parathyroidectomy, kidney transplant, death, or end of data (December 31, 2018). Analyses of mean PTH, Ca, and Phos, as well as target achievement of PTH, Ca, and Phos were conducted over a 9-month period. Discontinuation with etelcalcetide was measured with the Kaplan-Meier estimator. <b><i>Results:</i></b> There were 1,346 cinacalcet patients (mean age 60.5 years, 43.5% female, and 47.1% Black) and 1,255 etelcalcetide patients (mean age 63.4 years, 46.6% female, and 38.5% Black). At baseline, the proportions in target were similar for etelcalcetide versus cinacalcet: 36 versus 38% for PTH, 79 versus 80% for Ca, and 43 versus 44% for Phos. Overall, 40–47% of cinacalcet users and 48–62% of etelcalcetide users were observed to be in target for PTH over 9 months. The proportion in target for Phos ranged from 41 to 46% for cinacalcet and 46–51% for etelcalcetide. The proportion in target for Ca ranged from 74 to 78% for cinacalcet and 60–73% for etelcalcetide. Etelcalcetide 12-month discontinuation was 37.4%. <b><i>Conclusion:</i></b> Both calcimimetics were effective in keeping PTH, Ca, and Phos levels within target. Patients receiving etelcalcetide tended to have lower laboratory values for PTH, Ca, and Phos over time, while patients receiving cinacalcet tended to be more likely to be in target for Ca over time.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
bill完成签到,获得积分10
1秒前
饺子猫应助萨尔莫斯采纳,获得10
2秒前
梦游菌完成签到 ,获得积分10
4秒前
zhangwenjie完成签到 ,获得积分10
5秒前
詹姆斯哈登完成签到,获得积分10
16秒前
Criminology34应助科研通管家采纳,获得10
23秒前
Criminology34应助科研通管家采纳,获得10
23秒前
叶先生完成签到 ,获得积分10
26秒前
Ray完成签到 ,获得积分10
52秒前
MS903完成签到 ,获得积分10
55秒前
Heart_of_Stone完成签到 ,获得积分10
1分钟前
Cherish发布了新的文献求助20
1分钟前
oscar完成签到,获得积分10
1分钟前
huiluowork完成签到 ,获得积分10
1分钟前
光亮若翠完成签到,获得积分10
1分钟前
hxz完成签到 ,获得积分10
1分钟前
千帆破浪完成签到 ,获得积分10
2分钟前
美好灵寒完成签到 ,获得积分10
2分钟前
还单身的心情完成签到 ,获得积分10
2分钟前
Criminology34应助科研通管家采纳,获得10
2分钟前
Criminology34应助科研通管家采纳,获得10
2分钟前
NexusExplorer应助科研通管家采纳,获得10
2分钟前
2分钟前
劳伦斯完成签到 ,获得积分10
2分钟前
高高的书本完成签到,获得积分10
3分钟前
踏雪完成签到,获得积分10
3分钟前
行走的猫完成签到 ,获得积分10
3分钟前
wushuimei完成签到 ,获得积分10
3分钟前
谭凯文完成签到 ,获得积分10
3分钟前
酷酷的紫南完成签到 ,获得积分10
3分钟前
zydaphne完成签到 ,获得积分10
4分钟前
DHW1703701完成签到,获得积分10
4分钟前
LFZ完成签到 ,获得积分20
4分钟前
znchick完成签到,获得积分10
4分钟前
4分钟前
Criminology34应助科研通管家采纳,获得10
4分钟前
JamesPei应助科研通管家采纳,获得10
4分钟前
wodetaiyangLLL完成签到 ,获得积分10
4分钟前
wayne完成签到 ,获得积分10
4分钟前
马成双完成签到 ,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Encyclopedia of Reproduction Third Edition 3000
Comprehensive Methanol Science Production, Applications, and Emerging Technologies 2000
化妆品原料学 1000
《药学类医疗服务价格项目立项指南(征求意见稿)》 1000
The Political Psychology of Citizens in Rising China 600
1st Edition Sports Rehabilitation and Training Multidisciplinary Perspectives By Richard Moss, Adam Gledhill 600
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5635451
求助须知:如何正确求助?哪些是违规求助? 4736313
关于积分的说明 14990312
捐赠科研通 4793200
什么是DOI,文献DOI怎么找? 2560307
邀请新用户注册赠送积分活动 1520336
关于科研通互助平台的介绍 1480599